Offices

We continue to expand our footprint to better service our partners and customers. For more information on CPDC’s locations please contact us.

Capabilities & Services

  • Corporate Headquarters
  • Discovery
  • Radiopharmaceutical R&D Services
  • Radiopharmaceutical Manufacturing Services
  • PET and Therapeutic Radiopharmaceutical Manufacturing & Distribution
  • FDA and Health Canada Inspected Facilities

Capabilities & Services

  • PET Radiopharmaceutical Manufacturing & Distribution
  • Health Canada Inspected Facilities

Capabilities & Services

  • CanProbe Partnership
  • Joint Venture between University Health Network (UHN) and CPDC
  • Radiopharmaceutical Development, Manufacturing & Distribution

Centre for Probe Development and Commercialization (CPDC) Appoints New Head of Business Development

Hamilton, Ontario, November 16, 2018 – The Centre for Probe Development and Commercialization (CPDC) is proud to introduce the new Head of Business Development, Bruno Paquin, PhD. Bruno comes to us with years of experience in research and development and he brings with him extensive knowledge of scientific operations in life and health sciences, as

CPDC’s Discovery Team is experienced in oncology, immuno-oncology, and neurology models.

CPDC and University Health Network have created a joint venture, CanProbe, to accelerate the clinical development of molecular imaging probes.

CPDC’s manufacturing facilities are approved by both Health Canada and the US FDA for the production of positron emitting radiopharmaceuticals.

Global drug companies are using CPDC’s know-how and world-class facilities to develop and test new drugs and molecular probes.

During medical isotope shortages, CPDC can provide substitutes for use in bone scans and imaging kidney function.

CPDC can create PET and SPECT imaging companions for small molecules, peptides, antibodies and other biologics.

CPDC works with all therapeutic and diagnostic isotopes, and has extensive expertise with alpha and beta emitting nuclides.

Cyclotrons can be used to produce enough Tc-99m within 6 hours to enable over 500 nuclear imaging scans.

Molecular imaging probes can show a tumour’s biochemical response to treatment in just a few days, unlike conventional modes like MRI or CT, which may not show a change in tumour size for several weeks.

ARTMS Products Inc. has been created by Triumf, BCCA, LHRI and CPDC to commercialize jointly-developed technology for production of Tc-99m on standard medical cyclotrons.

Molecular PET imaging probes are used primarily to diagnose cancer, heart disease and neurological conditions.